Alzamend Neuro (Alzamend Neuro) Cash-to-Debt : No Debt ⁽¹⁾ (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Alzamend Neuro Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Alzamend Neuro's cash to debt ratio for the quarter that ended in Jan. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Alzamend Neuro could pay off its debt using the cash in hand for the quarter that ended in Jan. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Alzamend Neuro's Cash-to-Debt or its related term are showing as below:

ALZN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12 Med: No Debt Max: No Debt
Current: No Debt

During the past 5 years, Alzamend Neuro's highest Cash to Debt Ratio was No Debt. The lowest was 0.12. And the median was No Debt.

ALZN's Cash-to-Debt is ranked better than
99.74% of 1540 companies
in the Biotechnology industry
Industry Median: 6.52 vs ALZN: No Debt

Alzamend Neuro Cash-to-Debt Historical Data

The historical data trend for Alzamend Neuro's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Alzamend Neuro Cash-to-Debt Chart

Alzamend Neuro Annual Data

Trend

Apr19

Apr20

Apr21

Apr22

Apr23

Cash-to-Debt

No Debt

5.76

No Debt

Alzamend Neuro Quarterly Data
	Apr19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash-to-Debt	Get a 7-Day Free Trial													No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Alzamend Neuro's Cash-to-Debt

For the Biotechnology subindustry, Alzamend Neuro's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alzamend Neuro's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzamend Neuro's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Alzamend Neuro's Cash-to-Debt falls into.

Alzamend Neuro Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Alzamend Neuro's Cash to Debt Ratio for the fiscal year that ended in Apr. 2023 is calculated as:

Alzamend Neuro had no debt ⁽¹⁾.

Alzamend Neuro's Cash to Debt Ratio for the quarter that ended in Jan. 2024 is calculated as:

Alzamend Neuro had no debt ⁽¹⁾.

Alzamend Neuro (NAS:ALZN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Alzamend Neuro Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Alzamend Neuro's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Alzamend Neuro (Alzamend Neuro) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzamend Neuro Inc (NAS:ALZN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326

Website

https://www.alzamend.com

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Executives

Ault Milton C Iii	10 percent owner	11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 240, LAS VEGAS NV 89141
David J Katzoff	officer: Chief Operating Officer	201 SHIPYARD WAY, NEWPORT BEACH CA 92663
Stephan Jackman	director, officer: Chief Executive Officer	C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Lynne Fahey Mcgrath	director	28145 CEDAR POINT RD., EASTON MD 21601
Mark Gustafson	director	10691 ROSECROFT CRESCENT, RICHMOND A1 V7A 2H9
William B. Horne	director	C/O AULT ALLIANCE, INC., 940 SOUTH COAST DRIVE, SUITE 200, COSTA MESA CA 92626
Henry Carl Nisser	director, officer: Exec VP and General Counsel	100 PARK AVENUE, SUITE 1658A, NEW YORK NY 10017
Kenneth S Cragun	officer: SVP of Finance	3775 CHIPPEWA CIRCLE, CORONA CA 92881
Jeffrey Oram	director	15 ORCHARD STREET, MENDHAM NJ 07945
Escalona Lien	officer: Chief Financial Officer	C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Andrew H. Woo	director	2021 SANTA MONICA BLVD., SUITE 525E, SANTA MONICA CA 90404